KR20240035480A - 염증성 질병의 치료 - Google Patents

염증성 질병의 치료 Download PDF

Info

Publication number
KR20240035480A
KR20240035480A KR1020247002501A KR20247002501A KR20240035480A KR 20240035480 A KR20240035480 A KR 20240035480A KR 1020247002501 A KR1020247002501 A KR 1020247002501A KR 20247002501 A KR20247002501 A KR 20247002501A KR 20240035480 A KR20240035480 A KR 20240035480A
Authority
KR
South Korea
Prior art keywords
compound
inhibitors
day
treatment
paragraph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247002501A
Other languages
English (en)
Korean (ko)
Inventor
저스틴 다오
르네 알렉산드르 갈리엔
막달레나 욘코바 펫코바
크리스천 알렉산더 시메이어
에두아르 헬롯
나탈리아 루에다 린콘
Original Assignee
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈라파고스 엔.브이. filed Critical 갈라파고스 엔.브이.
Publication of KR20240035480A publication Critical patent/KR20240035480A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020247002501A 2021-07-12 2022-07-11 염증성 질병의 치료 Pending KR20240035480A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21305971 2021-07-12
EP21305971.0 2021-07-12
EP22315039.2 2022-02-24
EP22315039 2022-02-24
PCT/EP2022/069362 WO2023285405A1 (en) 2021-07-12 2022-07-11 Treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
KR20240035480A true KR20240035480A (ko) 2024-03-15

Family

ID=82748704

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002501A Pending KR20240035480A (ko) 2021-07-12 2022-07-11 염증성 질병의 치료

Country Status (9)

Country Link
US (1) US20240325404A1 (enExample)
EP (1) EP4370128A1 (enExample)
JP (1) JP2024524631A (enExample)
KR (1) KR20240035480A (enExample)
AU (1) AU2022310901A1 (enExample)
CA (1) CA3225221A1 (enExample)
IL (1) IL309946A (enExample)
MX (1) MX2024000517A (enExample)
WO (1) WO2023285405A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
AU2022310901A1 (en) 2024-02-22
JP2024524631A (ja) 2024-07-05
MX2024000517A (es) 2024-01-31
EP4370128A1 (en) 2024-05-22
US20240325404A1 (en) 2024-10-03
IL309946A (en) 2024-03-01
WO2023285405A1 (en) 2023-01-19
CA3225221A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
EP2970257B1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20230346820A1 (en) Methods and compositions for the treatment of sars-cov-2
EP3900717B1 (en) Vidofludimus for use in the treatment or prevention of viral diseases
JP2013512911A (ja) 癌治療用併用療法及び前記療法用診断アッセイ
CA3105485C (en) Pyrrolo[1,2-b]pyridazine derivatives
EP3220912A1 (en) Tlr inhibitor and bruton's tyrosine kinase inhibitor combinations
CN111053768A (zh) 用于治疗黑素瘤的药物组合
EP3308786A1 (en) Fgfr regulaton for the treatment of viral infections
US20240390378A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US20240024308A1 (en) Tlr7/8 antagonists for the treatment of coronavirus infections
KR20230044446A (ko) 급성 호흡기 장애의 치료 방법
Penman et al. Safety perspectives on presently considered drugs for the treatment of COVID‐19
Yuan et al. New drug approvals for 2022: Synthesis and clinical applications
WO2021216814A1 (en) Btk inhibitors to treat pulmonary distress in covid-19 patients
Grajales et al. Unveiling abrocitinib: a thorough examination of the 2022 USFDA-approved treatment for atopic dermatitis (AD)
KR20260042485A (ko) 궤양성 대장염의 치료를 위한 오베파지모드
US20220133751A1 (en) Methods of treating myeloproliferative disorders
CN117677387A (zh) 炎性疾病的治疗
WO2023161326A1 (en) Compound for use in and methods of treatment of inflammatory diseases
JP2022517951A (ja) 骨髄異形成症候群を処置するためのａｌｋ５阻害剤
US20240325404A1 (en) Treatment of inflammatory diseases
TW202545950A (zh) Ｓａｒｓ－ｃｏｖ２主要蛋白酶抑制劑
KR102517456B1 (ko) 섬유아세포 성장인자 11을 유효성분으로 포함하는 항바이러스 조성물
WO2023161327A1 (en) Compound for use in and methods of treatment of inflammatory diseases
US20240100025A1 (en) Materials and Methods for Treating Viral and Other Medical Conditions

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000